首页 > 最新文献

Frontiers in Pharmacology最新文献

英文 中文
Natural products modulate programmed cell death signaling mechanism for treating endometriosis: a review. 天然产物调节程序性细胞死亡信号机制治疗子宫内膜异位症:综述。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1742212
Zhen Zhao, Fangyuan Liu, Yang Yu, Ying Shen, Danni Ding, Fengjuan Han

Endometriosis (EMs) is a gynecological inflammatory disease that depends on estrogen. Its chief symptoms include dysmenorrhea, chronic pelvic pain, reduced fertility, and pelvic masses. Although various hormonal therapies and surgical treatments are available, their long-term effectiveness is limited, recurrence rates are high, and side effects are significant. Programmed cell death (PCD) is a genetically regulated mechanism of cell clearance that includes apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Numerous studies showed that dysregulation of PCD is strongly associated with the development of EMs, suggesting that targeting key molecular mechanisms of PCD could be a promising therapeutic strategy. Natural products, known for their multitarget activity and low toxicity, show unique advantages in modulating PCD in EMs. This review elucidates the regulatory mechanisms of various PCD pathways in EMs and their interactions with key signaling cascades, including PI3K/Akt/mTOR, MAPK, NF-κB, and Bcl-2. Furthermore, it explores how natural products modulate these PCD mechanisms and related pathways, providing insights into their therapeutic potential at the molecular level. We used "endometriosis," "programmed cell death," "natural products", and "signaling pathway" as keywords to systematically search the PubMed, Web of Science, and CNKI databases for relevant literature published in the past 10 years. A total of 55 studies were included, highlighting recent advances in regulating EMs progression through PCD modulation by natural products. The goal of this review is to provide a theoretical foundation for improving current treatments for EMs and to offer practical recommendations for future research.

子宫内膜异位症(EMs)是一种依赖雌激素的妇科炎症性疾病。其主要症状包括痛经、慢性盆腔疼痛、生育能力下降和盆腔肿块。虽然有各种激素疗法和手术治疗,但它们的长期疗效有限,复发率高,副作用显著。程序性细胞死亡(PCD)是一种基因调控的细胞清除机制,包括细胞凋亡、自噬、铁死亡、焦亡和坏死死亡。大量研究表明,PCD的失调与em的发展密切相关,这表明针对PCD的关键分子机制可能是一种很有前途的治疗策略。天然产物以其多靶点活性和低毒性而闻名,在调节EMs中的PCD方面显示出独特的优势。本文综述了em中各种PCD通路的调控机制及其与关键信号级联的相互作用,包括PI3K/Akt/mTOR、MAPK、NF-κB和Bcl-2。此外,它还探讨了天然产物如何调节这些PCD机制和相关途径,从而在分子水平上深入了解它们的治疗潜力。我们以“子宫内膜异位症”、“程序性细胞死亡”、“天然产物”、“信号通路”为关键词,系统检索PubMed、Web of Science、CNKI数据库近10年发表的相关文献。共纳入了55项研究,强调了通过天然产物PCD调节调节EMs进展的最新进展。本综述的目的是为改善目前的治疗方法提供理论基础,并为未来的研究提供实用建议。
{"title":"Natural products modulate programmed cell death signaling mechanism for treating endometriosis: a review.","authors":"Zhen Zhao, Fangyuan Liu, Yang Yu, Ying Shen, Danni Ding, Fengjuan Han","doi":"10.3389/fphar.2026.1742212","DOIUrl":"10.3389/fphar.2026.1742212","url":null,"abstract":"<p><p>Endometriosis (EMs) is a gynecological inflammatory disease that depends on estrogen. Its chief symptoms include dysmenorrhea, chronic pelvic pain, reduced fertility, and pelvic masses. Although various hormonal therapies and surgical treatments are available, their long-term effectiveness is limited, recurrence rates are high, and side effects are significant. Programmed cell death (PCD) is a genetically regulated mechanism of cell clearance that includes apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Numerous studies showed that dysregulation of PCD is strongly associated with the development of EMs, suggesting that targeting key molecular mechanisms of PCD could be a promising therapeutic strategy. Natural products, known for their multitarget activity and low toxicity, show unique advantages in modulating PCD in EMs. This review elucidates the regulatory mechanisms of various PCD pathways in EMs and their interactions with key signaling cascades, including PI3K/Akt/mTOR, MAPK, NF-κB, and Bcl-2. Furthermore, it explores how natural products modulate these PCD mechanisms and related pathways, providing insights into their therapeutic potential at the molecular level. We used \"endometriosis,\" \"programmed cell death,\" \"natural products\", and \"signaling pathway\" as keywords to systematically search the PubMed, Web of Science, and CNKI databases for relevant literature published in the past 10 years. A total of 55 studies were included, highlighting recent advances in regulating EMs progression through PCD modulation by natural products. The goal of this review is to provide a theoretical foundation for improving current treatments for EMs and to offer practical recommendations for future research.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1742212"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ability of SABRE, a new quantitative receptor function model, to quantify receptor binding from even challenging concentration-effect data with a single unified fit. SABRE是一种新的定量受体功能模型,即使是具有挑战性的浓度效应数据,也可以通过单一的统一拟合来量化受体结合。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1715771
Barbara Olah, Vera Tarjanyi, Gabor Viczjan, Ignac Ovari, Andras Csoto, Zoltan Szilvassy, Bela Juhasz, Judit Zsuga, Rudolf Gesztelyi, Tamas Erdei

The Signal Amplification, Binding affinity, and Receptor-activation Efficacy (SABRE) model is the most recent general and quantitative model of receptor function. A specific extension of the SABRE model enables the determination of Kd (the equilibrium dissociation constant of the agonist-receptor complex) and q (the fraction of receptors remaining operable after pretreatment with an irreversible receptor antagonist) from exclusively functional data. In the present investigation, we reevaluated the concentration-effect (E/c) data of our related recent study on the SABRE model to assess the properties of our newly developed multiline model, inspired by professional criticism of our previous study in question. We have found this multiline model, constructed within the framework of the SABRE model, to be capable of providing reliable results via one global fitting (i.e., with a single unified fit), even for our somewhat challenging data (containing some uncertainty). The multiline model that proved to be the most suitable for the current data was a relatively complex, six-model global fitting. These results further emphasize the significance of finding the best way to fit the equations of the SABRE model to the functional data to be evaluated.

信号放大、结合亲和力和受体激活功效(SABRE)模型是最新的受体功能通用定量模型。SABRE模型的一个特殊扩展,可以从专门的功能数据中确定Kd(激动剂-受体复合物的平衡解离常数)和q(用不可逆受体拮抗剂预处理后仍可操作的受体的比例)。在本研究中,我们重新评估了我们最近在SABRE模型上相关研究的浓度效应(E/c)数据,以评估我们新开发的多线模型的性质,灵感来自于对我们之前研究的专业批评。我们发现,在SABRE模型框架内构建的这个多线模型能够通过一个全局拟合(即,使用单一的统一拟合)提供可靠的结果,即使对于我们的一些具有挑战性的数据(包含一些不确定性)也是如此。事实证明,最适合当前数据的多线模型是一个相对复杂的六模型全球拟合。这些结果进一步强调了寻找将SABRE模型方程拟合到待评估的功能数据的最佳方法的重要性。
{"title":"The ability of SABRE, a new quantitative receptor function model, to quantify receptor binding from even challenging concentration-effect data with a single unified fit.","authors":"Barbara Olah, Vera Tarjanyi, Gabor Viczjan, Ignac Ovari, Andras Csoto, Zoltan Szilvassy, Bela Juhasz, Judit Zsuga, Rudolf Gesztelyi, Tamas Erdei","doi":"10.3389/fphar.2026.1715771","DOIUrl":"10.3389/fphar.2026.1715771","url":null,"abstract":"<p><p>The Signal Amplification, Binding affinity, and Receptor-activation Efficacy (SABRE) model is the most recent general and quantitative model of receptor function. A specific extension of the SABRE model enables the determination of K<sub>d</sub> (the equilibrium dissociation constant of the agonist-receptor complex) and q (the fraction of receptors remaining operable after pretreatment with an irreversible receptor antagonist) from exclusively functional data. In the present investigation, we reevaluated the concentration-effect (E/c) data of our related recent study on the SABRE model to assess the properties of our newly developed multiline model, inspired by professional criticism of our previous study in question. We have found this multiline model, constructed within the framework of the SABRE model, to be capable of providing reliable results <i>via</i> one global fitting (i.e., with a single unified fit), even for our somewhat challenging data (containing some uncertainty). The multiline model that proved to be the most suitable for the current data was a relatively complex, six-model global fitting. These results further emphasize the significance of finding the best way to fit the equations of the SABRE model to the functional data to be evaluated.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1715771"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: Rhodomyrtus tomentosa (Aiton) Hassk. (haramonting) protects against allethrin-exposed pulmo damage in rats: mechanistic interleukins. 牵回:毛囊红颊肌。(haramonting):机械性白细胞介素(mechanistic interleukin)。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1786993

[This retracts the article DOI: 10.3389/fphar.2024.1343936.].

[本文撤回文章DOI: 10.3389/fphar.2024.1343936.]。
{"title":"Retraction: <i>Rhodomyrtus tomentosa (Aiton) Hassk</i>. (haramonting) protects against allethrin-exposed pulmo damage in rats: mechanistic interleukins.","authors":"","doi":"10.3389/fphar.2026.1786993","DOIUrl":"https://doi.org/10.3389/fphar.2026.1786993","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fphar.2024.1343936.].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1786993"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12896213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protective effects of curcumin against chemical-induced toxicity in the male reproductive system: a systematic review. 姜黄素对男性生殖系统化学毒性的保护作用:系统综述。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1749370
Mitra Tarlan, Nillofar Heidrizadeh, Sara Gooharpoor, Omid Tavallaei, Saeed Khazayel, Mohamad Hosein Farzaei, Javier Echeverría

Background: Curcumin is a biologically active substance present in turmeric. It has recently been suggested for its protective potential against a wide variety of chemical-induced toxicities.

Purpose: This systematic review aims to summarize current evidence on the protective effects of curcumin against chemical-induced toxicity, with particular emphasis on its impact on the male reproductive system.

Methods: A literature search was conducted using the major databases PubMed®, Scopus®, Web of Science®, and ScienceDirect®, up to December 2024. This review encompassed studies assessing curcumin's protective role against chemical toxicity, both in vitro and in vivo. Extracted data included the type of chemical agent, dosage, curcumin formulation, and reported toxicity outcomes.

Results and discussion: A total of 31 studies were included in the present review based on the established inclusion criteria. The toxicants studied contained heavy metals (lead and cadmium), pesticides (e.g., Malathion), and industrial solvents (notably titanium dioxide nanoparticles). Curcumin has demonstrated significant protective effects through multiple mechanisms, including antioxidant activity, anti-inflammatory effects, and modulation of detoxification enzymes. Interestingly, curcumin supplementation was associated with reduced oxidative stress markers and improved histopathological findings across various animal models. The effective dose varied widely across studies, with most showing positive effects at doses between 50 mg/kg and 200 mg/kg.

Conclusion: The results of this systematic review suggest that curcumin holds promise for preventing various chemical-induced toxicities. Its diversified mechanisms of action show promise as a therapeutic agent for the relief of chemical toxicity. Nonetheless, additional studies are required to determine the most effective dosing strategies, examine bioavailability, and assess the safety of long-term use.

背景:姜黄素是存在于姜黄中的一种生物活性物质。最近有人提出,它具有防止多种化学物质引起的毒性的保护潜力。目的:本综述综述了姜黄素对化学毒性的保护作用,重点介绍了姜黄素对男性生殖系统的影响。方法:使用PubMed®、Scopus®、Web of Science®和ScienceDirect®等主要数据库进行文献检索,检索时间截止到2024年12月。本文综述了姜黄素在体内和体外对化学毒性的保护作用。提取的数据包括化学制剂的类型、剂量、姜黄素配方和报告的毒性结果。结果和讨论:根据既定的纳入标准,本综述共纳入了31项研究。所研究的有毒物质包括重金属(铅和镉)、杀虫剂(如马拉硫磷)和工业溶剂(特别是二氧化钛纳米颗粒)。姜黄素通过多种机制显示出显著的保护作用,包括抗氧化活性、抗炎作用和调节解毒酶。有趣的是,在各种动物模型中,姜黄素补充剂与氧化应激标志物的减少和组织病理学结果的改善有关。不同研究的有效剂量差异很大,在50毫克/公斤至200毫克/公斤的剂量范围内,大多数研究显示出积极作用。结论:本系统综述提示姜黄素具有预防多种化学物质引起的毒性的作用。其多种作用机制显示出其作为缓解化学毒性的治疗剂的前景。尽管如此,还需要进一步的研究来确定最有效的给药策略,检查生物利用度,并评估长期使用的安全性。
{"title":"Protective effects of curcumin against chemical-induced toxicity in the male reproductive system: a systematic review.","authors":"Mitra Tarlan, Nillofar Heidrizadeh, Sara Gooharpoor, Omid Tavallaei, Saeed Khazayel, Mohamad Hosein Farzaei, Javier Echeverría","doi":"10.3389/fphar.2026.1749370","DOIUrl":"10.3389/fphar.2026.1749370","url":null,"abstract":"<p><strong>Background: </strong>Curcumin is a biologically active substance present in turmeric. It has recently been suggested for its protective potential against a wide variety of chemical-induced toxicities.</p><p><strong>Purpose: </strong>This systematic review aims to summarize current evidence on the protective effects of curcumin against chemical-induced toxicity, with particular emphasis on its impact on the male reproductive system.</p><p><strong>Methods: </strong>A literature search was conducted using the major databases PubMed®, Scopus®, Web of Science®, and ScienceDirect®, up to December 2024. This review encompassed studies assessing curcumin's protective role against chemical toxicity, both <i>in vitro</i> and <i>in vivo</i>. Extracted data included the type of chemical agent, dosage, curcumin formulation, and reported toxicity outcomes.</p><p><strong>Results and discussion: </strong>A total of 31 studies were included in the present review based on the established inclusion criteria. The toxicants studied contained heavy metals (lead and cadmium), pesticides (e.g., Malathion), and industrial solvents (notably titanium dioxide nanoparticles). Curcumin has demonstrated significant protective effects through multiple mechanisms, including antioxidant activity, anti-inflammatory effects, and modulation of detoxification enzymes. Interestingly, curcumin supplementation was associated with reduced oxidative stress markers and improved histopathological findings across various animal models. The effective dose varied widely across studies, with most showing positive effects at doses between 50 mg/kg and 200 mg/kg.</p><p><strong>Conclusion: </strong>The results of this systematic review suggest that curcumin holds promise for preventing various chemical-induced toxicities. Its diversified mechanisms of action show promise as a therapeutic agent for the relief of chemical toxicity. Nonetheless, additional studies are required to determine the most effective dosing strategies, examine bioavailability, and assess the safety of long-term use.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1749370"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases. 药物性男性不育症:使用FAERS和EudraVigilance数据库的真实世界研究。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1765071
Zhuozhi Gong, Jing He, Qiujian Feng, Dong Liu, Shengjing Liu

Objective: To systematically identify medications potentially causing male infertility or sperm abnormalities and provide risk alerts for clinical practice.

Methods: A pharmacovigilance study was conducted using the FAERS database (Q1 2004-Q2 2025) and EudraVigilance (EV) database (January 2002-October 2025). Adverse events related to male reproductive toxicity were screened using the MedDRA dictionary. Drug safety signals were detected using ROR, PRR, IC, and EBGM, with reliability enhanced through cross-database validation and dechallenge/rechallenge analyses.

Results: The study included 1,955 FAERS cases and 1,384 from EV, with a median patient age of 35 years and 37% being reproductive-age males (18-44 years). The median time to event onset was 132 days, consistent with the spermatogenic cycle. Cross-validation identified 19 high-risk drugs, including hormonal agents (finasteride, dutasteride, testosterone), antineoplastic drugs (bleomycin, vinblastine, hydroxycarbamide), and antidepressants (citalopram, paroxetine). Finasteride satisfied both dechallenge and rechallenge criteria, providing strong evidence for causality. Signals concentrated in three major categories: genitourinary and sex hormones, dermatological preparations, and antineoplastic agents. Stratified analysis showed that both consumer and healthcare professional reports identified 13 high-risk drugs, with high consistency for major drugs (finasteride, testosterone), confirming result robustness.

Conclusion: This pharmacovigilance study identified 19 high-risk drugs for male infertility across hormonal agents, antineoplastic drugs, and antidepressants. These findings underscore pre-prescription, risk-stratified fertility counseling for reproductive-age males, prioritizing sperm cryopreservation before chemotherapy and considering it selectively for 5α-reductase inhibitors, testosterone, or antidepressants.

目的:系统识别可能导致男性不育或精子异常的药物,为临床提供风险提示。方法:采用FAERS数据库(2004-Q2 2025)和EudraVigilance (EV)数据库(2002年1月- 2025年10月)进行药物警戒研究。使用MedDRA词典筛选与男性生殖毒性相关的不良事件。采用ROR、PRR、IC和EBGM检测药物安全性信号,并通过跨数据库验证和挑战/再挑战分析提高可靠性。结果:该研究包括1955例FAERS和1384例EV,患者中位年龄为35岁,37%为育龄男性(18-44岁)。事件发生的中位时间为132天,与生精周期一致。交叉验证确定了19种高危药物,包括激素药物(非那雄胺、度他雄胺、睾酮)、抗肿瘤药物(博来霉素、长春碱、羟脲)和抗抑郁药物(西酞普兰、帕罗西汀)。非那雄胺满足挑战和再挑战标准,为因果关系提供了强有力的证据。信号主要集中在三大类:泌尿生殖系统激素和性激素、皮肤病制剂和抗肿瘤药物。分层分析显示,消费者和医疗保健专业人员的报告都确定了13种高风险药物,主要药物(非那雄胺、睾酮)的一致性很高,证实了结果的稳健性。结论:这项药物警戒研究确定了19种男性不育的高危药物,包括激素药物、抗肿瘤药物和抗抑郁药物。这些发现强调了对育龄男性的处方前、风险分层生育咨询,在化疗前优先考虑精子冷冻保存,并选择性地考虑5α-还原酶抑制剂、睾酮或抗抑郁药。
{"title":"Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases.","authors":"Zhuozhi Gong, Jing He, Qiujian Feng, Dong Liu, Shengjing Liu","doi":"10.3389/fphar.2026.1765071","DOIUrl":"10.3389/fphar.2026.1765071","url":null,"abstract":"<p><strong>Objective: </strong>To systematically identify medications potentially causing male infertility or sperm abnormalities and provide risk alerts for clinical practice.</p><p><strong>Methods: </strong>A pharmacovigilance study was conducted using the FAERS database (Q1 2004-Q2 2025) and EudraVigilance (EV) database (January 2002-October 2025). Adverse events related to male reproductive toxicity were screened using the MedDRA dictionary. Drug safety signals were detected using ROR, PRR, IC, and EBGM, with reliability enhanced through cross-database validation and dechallenge/rechallenge analyses.</p><p><strong>Results: </strong>The study included 1,955 FAERS cases and 1,384 from EV, with a median patient age of 35 years and 37% being reproductive-age males (18-44 years). The median time to event onset was 132 days, consistent with the spermatogenic cycle. Cross-validation identified 19 high-risk drugs, including hormonal agents (finasteride, dutasteride, testosterone), antineoplastic drugs (bleomycin, vinblastine, hydroxycarbamide), and antidepressants (citalopram, paroxetine). Finasteride satisfied both dechallenge and rechallenge criteria, providing strong evidence for causality. Signals concentrated in three major categories: genitourinary and sex hormones, dermatological preparations, and antineoplastic agents. Stratified analysis showed that both consumer and healthcare professional reports identified 13 high-risk drugs, with high consistency for major drugs (finasteride, testosterone), confirming result robustness.</p><p><strong>Conclusion: </strong>This pharmacovigilance study identified 19 high-risk drugs for male infertility across hormonal agents, antineoplastic drugs, and antidepressants. These findings underscore pre-prescription, risk-stratified fertility counseling for reproductive-age males, prioritizing sperm cryopreservation before chemotherapy and considering it selectively for 5α-reductase inhibitors, testosterone, or antidepressants.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1765071"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beneficial effects of berberine in the treatment of diabetes and its complications. 小檗碱治疗糖尿病及其并发症的有益作用。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2025-01-01 DOI: 10.3389/fphar.2025.1701513
Shanyao Liu, Jie Shen, Fanghui Xu, Lu Niu, Fengchan Wang, Guojing Zhao

Coptis chinensis (Huanglian), a key component in numerous classical Chinese herbal formulas, is traditionally applied for treating metabolic diseases based on its activity including clear heat, dry dampness, purge fire, and detoxify. Berberine (BBR), one key active component from Coptis chinensis, was contained in numerous classical Chinese herbal formulas for improving insulin resistance and regulating blood glucose levels, making them applicable for diabetes mellitus (DM) treatment. Clinical trials confirm that BBR monotherapy reduces glycated hemoglobin (HbA1c) by 1.5% in T2DM patients comparable to metformin. This review aims to explore its applications and current research progress in DM therapy. This article systematically reviews the modern separation, extraction, and purification techniques for BBR, its molecular pharmacological mechanisms, and advances in novel delivery technologies for diabetes treatment. This review synthesizes evidence that BBR exerts its anti-diabetic effects through multi-tiered mechanisms converging on the amelioration of insulin resistance and systemic inflammation. The findings provide a theoretical foundation for optimizing BBR's clinical application and promote the transformation of traditional Chinese medicine from empirical usage to a scientific and standardized therapeutic paradigm. By integrating BBR's multi-target pharmacology with cutting-edge delivery technologies, this review provides a transformative perspective, positioning BBR not merely as a natural product but as a scaffold for the rational development of next-generation, multi-target diabetes therapeutics.

黄连(Coptis chinensis,黄连)是众多经典中草药配方中的关键成分,传统上用于治疗代谢性疾病,其活性包括清热、干湿、泻火和解毒。小檗碱(Berberine, BBR)是黄连(Coptis chinensis)的一种重要活性成分,被广泛应用于改善胰岛素抵抗和调节血糖水平的中药制剂中,可用于治疗糖尿病(DM)。临床试验证实,与二甲双胍相比,BBR单药治疗可使T2DM患者糖化血红蛋白(HbA1c)降低1.5%。现就其在糖尿病治疗中的应用及研究进展进行综述。本文系统地综述了BBR的现代分离、提取、纯化技术、分子药理机制,以及新型给药技术在糖尿病治疗中的进展。本文综述了BBR通过多层机制发挥其抗糖尿病作用的证据,包括改善胰岛素抵抗和全身性炎症。研究结果可为优化BBR的临床应用提供理论基础,促进中医从经验性用药向科学化、规范化的治疗范式转变。通过将BBR的多靶点药理学与尖端的给药技术相结合,本综述提供了一个变革性的视角,将BBR定位为不仅是一种天然产物,而且是下一代多靶点糖尿病治疗药物的合理开发的支架。
{"title":"Beneficial effects of berberine in the treatment of diabetes and its complications.","authors":"Shanyao Liu, Jie Shen, Fanghui Xu, Lu Niu, Fengchan Wang, Guojing Zhao","doi":"10.3389/fphar.2025.1701513","DOIUrl":"10.3389/fphar.2025.1701513","url":null,"abstract":"<p><p>Coptis chinensis (Huanglian), a key component in numerous classical Chinese herbal formulas, is traditionally applied for treating metabolic diseases based on its activity including clear heat, dry dampness, purge fire, and detoxify. Berberine (BBR), one key active component from Coptis chinensis, was contained in numerous classical Chinese herbal formulas for improving insulin resistance and regulating blood glucose levels, making them applicable for diabetes mellitus (DM) treatment. Clinical trials confirm that BBR monotherapy reduces glycated hemoglobin (HbA1c) by 1.5% in T2DM patients comparable to metformin. This review aims to explore its applications and current research progress in DM therapy. This article systematically reviews the modern separation, extraction, and purification techniques for BBR, its molecular pharmacological mechanisms, and advances in novel delivery technologies for diabetes treatment. This review synthesizes evidence that BBR exerts its anti-diabetic effects through multi-tiered mechanisms converging on the amelioration of insulin resistance and systemic inflammation. The findings provide a theoretical foundation for optimizing BBR's clinical application and promote the transformation of traditional Chinese medicine from empirical usage to a scientific and standardized therapeutic paradigm. By integrating BBR's multi-target pharmacology with cutting-edge delivery technologies, this review provides a transformative perspective, positioning BBR not merely as a natural product but as a scaffold for the rational development of next-generation, multi-target diabetes therapeutics.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1701513"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12895191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data-driven strategies for immunoradiotherapy in uveal melanoma: the role of artificial intelligence. 葡萄膜黑色素瘤免疫放射治疗的数据驱动策略:人工智能的作用。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1762154
Dongling Gu, Yi Feng, Hongyan Li

Uveal melanoma (UM) represents the most common primary intraocular malignancy in adults and remains a formidable clinical challenge due to its high metastatic potential and characteristically limited response to conventional systemic therapies. While the combination of radiotherapy and immunotherapy has emerged as a promising multimodal strategy for managing this complex malignancy, its efficacy is significantly constrained by profound individual variations in tumor biology, immune microenvironment composition, and dynamic treatment response patterns. In recent years, artificial intelligence (AI) has fundamentally transformed the landscape of precision oncology by enabling sophisticated image analysis, robust data-driven prediction, and seamless integration of heterogeneous multi-omics information. Within the specific context of uveal melanoma, AI-driven computational models have demonstrated significant potential to accurately predict therapeutic outcomes, quantitatively characterize the tumor immune microenvironment, and optimize radiotherapeutic strategies on a personalized basis. This comprehensive review critically examines and synthesizes recent progress in AI applications for immunoradiotherapy in uveal melanoma, systematically exploring their transformative potential to refine diagnostic accuracy, enhance treatment precision, and ultimately improve long-term patient outcomes through intelligent, data-driven personalized medicine approaches that bridge multiple disciplinary boundaries.

葡萄膜黑色素瘤(UM)是成人中最常见的原发性眼内恶性肿瘤,由于其高转移潜力和传统全身治疗的局限性,仍然是一个巨大的临床挑战。虽然放射治疗和免疫治疗的结合已成为治疗这种复杂恶性肿瘤的一种有前途的多模式策略,但其疗效受到肿瘤生物学、免疫微环境组成和动态治疗反应模式的深刻个体差异的显著限制。近年来,人工智能(AI)通过实现复杂的图像分析、稳健的数据驱动预测以及异构多组学信息的无缝集成,从根本上改变了精准肿瘤学的格局。在葡萄膜黑色素瘤的特定背景下,人工智能驱动的计算模型在准确预测治疗结果、定量表征肿瘤免疫微环境和个性化优化放射治疗策略方面显示出了巨大的潜力。这篇全面的综述批判性地检查和综合了人工智能在葡萄膜黑色素瘤免疫放射治疗中的应用的最新进展,系统地探索了它们的变革潜力,以提高诊断准确性,提高治疗精度,并最终通过跨越多学科界限的智能,数据驱动的个性化医疗方法改善患者的长期预后。
{"title":"Data-driven strategies for immunoradiotherapy in uveal melanoma: the role of artificial intelligence.","authors":"Dongling Gu, Yi Feng, Hongyan Li","doi":"10.3389/fphar.2026.1762154","DOIUrl":"10.3389/fphar.2026.1762154","url":null,"abstract":"<p><p>Uveal melanoma (UM) represents the most common primary intraocular malignancy in adults and remains a formidable clinical challenge due to its high metastatic potential and characteristically limited response to conventional systemic therapies. While the combination of radiotherapy and immunotherapy has emerged as a promising multimodal strategy for managing this complex malignancy, its efficacy is significantly constrained by profound individual variations in tumor biology, immune microenvironment composition, and dynamic treatment response patterns. In recent years, artificial intelligence (AI) has fundamentally transformed the landscape of precision oncology by enabling sophisticated image analysis, robust data-driven prediction, and seamless integration of heterogeneous multi-omics information. Within the specific context of uveal melanoma, AI-driven computational models have demonstrated significant potential to accurately predict therapeutic outcomes, quantitatively characterize the tumor immune microenvironment, and optimize radiotherapeutic strategies on a personalized basis. This comprehensive review critically examines and synthesizes recent progress in AI applications for immunoradiotherapy in uveal melanoma, systematically exploring their transformative potential to refine diagnostic accuracy, enhance treatment precision, and ultimately improve long-term patient outcomes through intelligent, data-driven personalized medicine approaches that bridge multiple disciplinary boundaries.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1762154"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022). 立法新的精神活性物质:从15年的英国死亡率数据(2007-2022)的教训。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2025-01-01 DOI: 10.3389/fphar.2025.1708335
Kirsten L Rock, Ric Treble, Caroline S Copeland

Background: Novel Psychoactive Substances (NPS) emerged in the early 2000s as chemically designed alternatives to circumvent laws which internationally control drugs. There is limited evidence that NPS are produced in the UK, whereas China has long been recognised as a primary source of NPS. This study aimed to evaluate the relative impact of UK, Chinese, and UN legislative controls on the availability of NPS in the UK, as evidenced by post-mortem detections of NPS in deaths.

Methods: Deaths reported to the National Programme on Substance Use Mortality (NPSUM) which occurred 2007-2022 were extracted for analysis. Drugs from the three major substance classes-opioids, stimulants and cannabinoids-which were detected in these deaths were categorised according to their control status as either classical substances (i.e., those under international control prior to 2007), NPS controlled in China, or other NPS.

Findings: Across all three drug classes, detections of classical substances dominated throughout the study period. Detections of NPS opioids-primarily fentanyl analogues-peaked in 2017, NPS stimulants-notably cathinones-in 2015, and synthetic cannabinoid receptor agonists in 2018 and 2021. Whilst UK legislative controls (the Misuse of Drugs Act 1971, Temporary Class Drug Orders, the Psychoactive Substances Act 2016) were generally implemented first, reductions in NPS detections were more closely associated with the introduction of Chinese legislations - in particular the 2021 Chinese generic ban on synthetic cannabinoids which resulted in an almost complete disappearance of these compounds in UK deaths in 2022.

Conclusion: The findings of this study indicate that the most effective way to reduce NPS availability in the UK is via legislation in producer countries, as evidenced by substantial declines in their detections in deaths following their control in China. This reliance on international controls places the UK in a vulnerable position, as its domestic drug landscape is being shaped largely by the pace and scope of independent international legislations. To achieve and maximise effectiveness, UK drug policy needs to integrate harm reduction measures alongside the introduction of legislative controls, whilst also encouraging international efforts to bring in global control of problem materials.

背景:新型精神活性物质(NPS)出现在21世纪初,作为化学设计的替代品,以规避国际管制药物的法律。有有限的证据表明NPS是在英国生产的,而中国长期以来一直被认为是NPS的主要来源。本研究旨在评估英国、中国和联合国立法控制对英国NPS可获得性的相对影响,这是由死亡病例尸检检测到的NPS所证明的。方法:提取2007-2022年国家物质使用死亡率规划(NPSUM)报告的死亡病例进行分析。在这些死亡中检测到的阿片类药物、兴奋剂和大麻素这三种主要物质类别的药物根据其管制状况分为经典物质(即2007年以前受国际管制的物质)、在中国受管制的新物质或其他新物质。结果:在所有三种药物类别中,经典物质的检测在整个研究期间占主导地位。NPS阿片类药物(主要是芬太尼类似物)的检测在2017年达到顶峰,NPS兴奋剂(尤其是卡西酮)的检测在2015年达到顶峰,合成大麻素受体激动剂的检测在2018年和2021年达到顶峰。虽然英国的立法控制(《1971年药物滥用法》、《临时类药物令》、《2016年精神活性物质法》)通常是首先实施的,但NPS检测的减少与中国立法的引入更密切相关——特别是2021年中国对合成大麻素的通用禁令,导致这些化合物在2022年英国死亡人数中几乎完全消失。结论:本研究的结果表明,在英国,减少NPS可用性的最有效方法是通过生产国的立法,这一点在中国控制NPS后,NPS的死亡检出率大幅下降。这种对国际管制的依赖使英国处于弱势地位,因为其国内毒品格局在很大程度上取决于独立国际立法的速度和范围。为了实现和最大限度地提高有效性,英国的毒品政策需要在引入立法控制的同时,将减少危害的措施结合起来,同时鼓励国际努力,对问题材料进行全球控制。
{"title":"Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022).","authors":"Kirsten L Rock, Ric Treble, Caroline S Copeland","doi":"10.3389/fphar.2025.1708335","DOIUrl":"10.3389/fphar.2025.1708335","url":null,"abstract":"<p><strong>Background: </strong>Novel Psychoactive Substances (NPS) emerged in the early 2000s as chemically designed alternatives to circumvent laws which internationally control drugs. There is limited evidence that NPS are produced in the UK, whereas China has long been recognised as a primary source of NPS. This study aimed to evaluate the relative impact of UK, Chinese, and UN legislative controls on the availability of NPS in the UK, as evidenced by post-mortem detections of NPS in deaths.</p><p><strong>Methods: </strong>Deaths reported to the National Programme on Substance Use Mortality (NPSUM) which occurred 2007-2022 were extracted for analysis. Drugs from the three major substance classes-opioids, stimulants and cannabinoids-which were detected in these deaths were categorised according to their control status as either classical substances (i.e., those under international control prior to 2007), NPS controlled in China, or other NPS.</p><p><strong>Findings: </strong>Across all three drug classes, detections of classical substances dominated throughout the study period. Detections of NPS opioids-primarily fentanyl analogues-peaked in 2017, NPS stimulants-notably cathinones-in 2015, and synthetic cannabinoid receptor agonists in 2018 and 2021. Whilst UK legislative controls (the Misuse of Drugs Act 1971, Temporary Class Drug Orders, the Psychoactive Substances Act 2016) were generally implemented first, reductions in NPS detections were more closely associated with the introduction of Chinese legislations - in particular the 2021 Chinese generic ban on synthetic cannabinoids which resulted in an almost complete disappearance of these compounds in UK deaths in 2022.</p><p><strong>Conclusion: </strong>The findings of this study indicate that the most effective way to reduce NPS availability in the UK is via legislation in producer countries, as evidenced by substantial declines in their detections in deaths following their control in China. This reliance on international controls places the UK in a vulnerable position, as its domestic drug landscape is being shaped largely by the pace and scope of independent international legislations. To achieve and maximise effectiveness, UK drug policy needs to integrate harm reduction measures alongside the introduction of legislative controls, whilst also encouraging international efforts to bring in global control of problem materials.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1708335"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1. 收缩:通过Her2, IL33, EGFR和MUC1在乳腺组织中作为一种新的抗癌分子策略。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1791496

[This retracts the article DOI: 10.3389/fphar.2024.1345645.].

[本文撤回文章DOI: 10.3389/fphar.2024.1345645.]。
{"title":"Retraction: <i>Rhodomyrtus tomentosa</i> as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1.","authors":"","doi":"10.3389/fphar.2026.1791496","DOIUrl":"https://doi.org/10.3389/fphar.2026.1791496","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fphar.2024.1345645.].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1791496"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12897496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Machine learning model for predicting the cold-heat pattern in Kampo medicine: a multicenter prospective observational study. 更正:预测汉布医学冷热模式的机器学习模型:一项多中心前瞻性观察研究。
IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 eCollection Date: 2026-01-01 DOI: 10.3389/fphar.2026.1789439
Ayako Maeda-Minami, Tetsuhiro Yoshino, Kotoe Katayama, Yuko Horiba, Hiroaki Hikiami, Yutaka Shimada, Takao Namiki, Eiichi Tahara, Kiyoshi Minamizawa, Shin-Ichi Muramatsu, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Hideki Mima, Kazushi Uneda, Tatsuya Nogami, Koichi Fukunaga, Kenji Watanabe

[This corrects the article DOI: 10.3389/fphar.2024.1412593.].

[这更正了文章DOI: 10.3389/fphar.2024.1412593.]。
{"title":"Correction: Machine learning model for predicting the cold-heat pattern in Kampo medicine: a multicenter prospective observational study.","authors":"Ayako Maeda-Minami, Tetsuhiro Yoshino, Kotoe Katayama, Yuko Horiba, Hiroaki Hikiami, Yutaka Shimada, Takao Namiki, Eiichi Tahara, Kiyoshi Minamizawa, Shin-Ichi Muramatsu, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Hideki Mima, Kazushi Uneda, Tatsuya Nogami, Koichi Fukunaga, Kenji Watanabe","doi":"10.3389/fphar.2026.1789439","DOIUrl":"https://doi.org/10.3389/fphar.2026.1789439","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fphar.2024.1412593.].</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"17 ","pages":"1789439"},"PeriodicalIF":4.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12895058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1